PF-08046050 + bevacizumab

PF-08046050 + bevacizumab is an experimental **combination therapy** currently being studied for advanced solid tumors, including colorectal cancer, gastric carcinoma, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma, non-squamous and squamous non-small cell lung cancer, small cell lung cancer, and other solid tumors that are difficult to treat[4][6][7][8]. **PF-08046050** (also known as SGN-CEACAM5C) is an **antibody-drug conjugate (ADC)** consisting of a humanized IgG1 monoclonal antibody targeting **CEA cell adhesion molecule 5 (CEACAM5)**, conjugated to the topoisomerase I inhibitor AMDCPT (aminomethyl-10,11-methylenedioxycamptothecin)[2][4][6][7][8]. It is designed to deliver cytotoxic payload specifically to CEACAM5-expressing tumor cells, causing DNA damage and cell death. **Bevacizumab** (Avastin) is a recombinant, humanized monoclonal antibody that targets **vascular endothelial growth factor A (VEGF-A)**, inhibiting angiogenesis (formation of new blood vessels) required for tumor growth and metastasis[1][5]. This combination leverages **targeted cytotoxicity** with PF-08046050 alongside anti-angiogenic effects from bevacizumab. Development is led by Pfizer and Sanofi for PF-08046050, and by Genentech/Roche for bevacizumab.

Other names

PF-08046050 + AvastinSGN-CEACAM5C + bevacizumab